These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19183926)

  • 1. [Rituximab in treatment for neuroimmunological diseases].
    Schröder A; Ellrichmann G; Chehab G; Schneider M; Linker RA; Gold R
    Nervenarzt; 2009 Feb; 80(2):155-6, 158-60, 162-5. PubMed ID: 19183926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab: current status as therapy for malignant and benign hematologic disorders.
    Abdulla NE; Ninan MJ; Markowitz AB
    BioDrugs; 2012 Apr; 26(2):71-82. PubMed ID: 22339395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.
    Dorvignit D; Palacios JL; Merino M; Hernández T; Sosa K; Casaco A; López-Requena A; Mateo de Acosta C
    MAbs; 2012; 4(4):488-96. PubMed ID: 22647435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
    Pescovitz MD
    Am J Transplant; 2006 May; 6(5 Pt 1):859-66. PubMed ID: 16611321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunologic effects of anti-B-lymphocyte antibodies].
    Cartron G
    Rev Med Interne; 2005 Oct; 26 Spec No 1():42-6. PubMed ID: 16475265
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20).
    Eisenberg R
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):345-50. PubMed ID: 17214580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
    Kennedy AD; Beum PV; Solga MD; DiLillo DJ; Lindorfer MA; Hess CE; Densmore JJ; Williams ME; Taylor RP
    J Immunol; 2004 Mar; 172(5):3280-8. PubMed ID: 14978136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD20-targeted therapy: the next generation of antibodies.
    van Meerten T; Hagenbeek A
    Semin Hematol; 2010 Apr; 47(2):199-210. PubMed ID: 20350667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
    Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
    Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cell depletion in the treatment of multiple sclerosis.
    Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
    Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
    Tanaka Y
    Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies.
    Pedersen AE; Jungersen MB; Pedersen CD
    Immunology; 2011 Jun; 133(2):239-45. PubMed ID: 21426340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development.
    Klink DT; van Elburg RM; Schreurs MW; van Well GT
    Clin Dev Immunol; 2008; 2008():271363. PubMed ID: 18596903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys.
    Nickerson-Nutter C; Tchistiakova L; Seth NP; Kasaian M; Sibley B; Olland S; Zollner R; Brady WA; Mohler KM; Baum P; Wahl A; Herber D; Vugmeyster Y; Wensel D; Wolfman NM; Gill D; Collins M; Dunussi-Joannopoulos K
    Rheumatology (Oxford); 2011 Jun; 50(6):1033-44. PubMed ID: 21258049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rituximab: a original biotherapy in auto-immune disorders].
    Sibilia J; Sordet C
    Rev Med Interne; 2005 Jun; 26(6):485-500. PubMed ID: 15936477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proposal for rituximab treatment in patients with myasthenia gravis].
    Konno S
    Rinsho Shinkeigaku; 2013; 53(11):1312-4. PubMed ID: 24291971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders.
    Lehmann-Horn K; Schleich E; Hertzenberg D; Hapfelmeier A; Kümpfel T; von Bubnoff N; Hohlfeld R; Berthele A; Hemmer B; Weber MS
    J Neuroinflammation; 2011 Oct; 8():146. PubMed ID: 22027448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanisms of action of rituximab in the elimination of tumor cells.
    Johnson P; Glennie M
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):3-8. PubMed ID: 12652458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.